Another predictive marker for PCa that affects the efficacy of taxane therapy is cSNP (rs4149117), located in SLCO1B3. Although SNPs are influencing pharmacotherapy, but still there are only a few genetic markers that have been used in pharmacotherapy or individualized treatment strategy for cancer patients [199]. Here, SLCO1B3 is linked to cancer.